Erythropoietin, the FDA, and oncology.
Steinbrook
Robert
R
rsteinbrook@attglobal.net
D026683:Advisory Committees; D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy*; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use*; D005102:Health Expenditures / Q000639:trends; D006397:Hematinics / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D019458:Insurance Coverage / Q000331:legislation & jurisprudence*; D006278:Medicare / Q000191:economics; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D011994:Recombinant Proteins; D014481:United States; D014486:United States Food and Drug Administration
D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa